Ascletis Gains FDA Approval to Advance Obesity Treatment to Phase III Trials

Ascletis Pharma Inc. has received U.S. FDA clearance to begin its Phase III ASC30 program for obesity and overweight. This program will involve 4,600 participants across the U.S., Canada, and Europe, representing a significant step in developing new therapies for these widespread health conditions. The advancement to Phase III indicates potential progress in addressing a major public health challenge.